RIKEN

Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings

Retrieved on: 
Tuesday, November 15, 2022

TOKYO, Nov 15, 2022 - (JCN Newswire) - The supercomputer Fugaku, jointly developed by RIKEN and Fujitsu, has successfully retained the top spot for six consecutive terms in multiple major high-performance computer rankings including HPCG and Graph500 BFS (Breadth-First Search), and has also taken second place for the TOP500 and third place for the HPL-AI rankings.

Key Points: 
  • TOKYO, Nov 15, 2022 - (JCN Newswire) - The supercomputer Fugaku, jointly developed by RIKEN and Fujitsu, has successfully retained the top spot for six consecutive terms in multiple major high-performance computer rankings including HPCG and Graph500 BFS (Breadth-First Search), and has also taken second place for the TOP500 and third place for the HPL-AI rankings.
  • The HPCG is a performance ranking for computing methods often used for real-world applications, and the Graph500 ranks systems based on graph analytic performance, an important element in data-intensive workloads.
  • The results this time were made with Fugaku's full complement of 158,976 nodes fit into 432 racks.
  • The top ranking on Graph500 was won by a collaboration involving RIKEN, Kyushu University, Fixstars Corporation, and Fujitsu.

Fujitsu develops quantum/HPC hybrid computing technology to optimize solution brokering for customers

Retrieved on: 
Tuesday, November 8, 2022

TOKYO, Nov 8, 2022 - (JCN Newswire) - Fujitsu today announced the development of quantum/HPC hybrid computing technology to optimize workload selection for customers.

Key Points: 
  • TOKYO, Nov 8, 2022 - (JCN Newswire) - Fujitsu today announced the development of quantum/HPC hybrid computing technology to optimize workload selection for customers.
  • Crucially, the technology allows users without specialized knowledge to use quantum simulators and HPC technology to provide effective solutions to real-world problems.
  • Fujitsu is currently working to develop a computing workload broker--a software technology that uses AI to automatically select the appropriate resources from advanced computing technologies and solutions, including large-scale cloud-based HPC, quantum computing, Digital Annealer, as well as quantum simulators to solve customers' complex problems.
  • In this way, the computing workload broker will enable high-speed calculations and solutions according to customers' specific needs.

Fujitsu launches "Fujitsu Computing as a Service (CaaS)" in Japan, new global co-creation partner program

Retrieved on: 
Tuesday, October 25, 2022

Fujitsu's new cloud services include "Fujitsu Computing as a Service HPC" (hereinafter CaaS HPC) as well as "Fujitsu Computing as a Service Digital Annealer" (hereinafter CaaS Digital Annealer) for developing and running simulations, AI technologies and combinatorial optimization applications.

Key Points: 
  • Fujitsu's new cloud services include "Fujitsu Computing as a Service HPC" (hereinafter CaaS HPC) as well as "Fujitsu Computing as a Service Digital Annealer" (hereinafter CaaS Digital Annealer) for developing and running simulations, AI technologies and combinatorial optimization applications.
  • Fujitsu offers CaaS as a cloud service portfolio that enables Fujitsu and its customers to jointly develop and implement applications and services using cutting-edge computing and software technologies.
  • The CaaS portfolio includes high-performance computing (HPC) technologies and Fujitsu's Quantum-Inspired Digital Annealer (1) as cloud services as well as technical consulting services.
  • By promoting co-creation with various partners, Fujitsu aims to further enhance the value of solutions offered under Fujitsu Uvance.

Honda Prize 2022 Awardee: Dr. Hidetoshi Katori, Professor, Graduate School of Engineering, University of Tokyo

Retrieved on: 
Friday, September 30, 2022

TOKYO, Sept. 30, 2022 /PRNewswire/ -- The Honda Foundation, the public-interest incorporated foundation established by Soichiro Honda and his younger brother Benjiro and currently led by President Hiroto Ishida, is pleased to announce that the Honda Prize 2022 willbe awarded to Dr. Hidetoshi Katori, Professor, the Graduate School of Engineering, The University of Tokyo (Chief Scientist and Team Leader, RIKEN), for inventing an optical lattice clock that is 1,000 times more precise than conventional atomic clocks.

Key Points: 
  • The Honda Prize, established in 1980 and awarded annually, is an international award recognizing the work of individuals or groups generating new knowledge that will drive the next generation from the standpoint of ecotechnology (*1).
  • Dr. Katori invented in 2001 a novel optical atomic clock that uses a large number of atoms trapped in an optical lattice to provide an ultra-high-precision time and frequency standard.
  • The improvement in accuracy of one second is expected to have an immeasurable impact on mankind.
  • The Prize will be awarded to Dr. Katori for this groundbreaking invention, which is worthy of the highest recognition.

Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs

Retrieved on: 
Thursday, July 21, 2022

February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (LiberoThera) to co-develop fully human GPCR antibodies using Biocytogens advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoTheras outstanding membrane antigen preparation technology.

Key Points: 
  • February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (LiberoThera) to co-develop fully human GPCR antibodies using Biocytogens advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoTheras outstanding membrane antigen preparation technology.
  • These antibody clones exhibit high affinity binding to human CCR8 with species cross-reactivity and good manufacturability.
  • This undoubtedly validates that LiberoThera's advanced antigen preparation technology synergizes with our RenMice KO platform to generate diverse fully human antibodies.
  • Biocytogens streamlined fully human antibody development platform greatly accelerates the translation of GPCR research.

Fujitsu Conducts Successful Large-scale Electromagnetic Wave Simulations for Space Industry, Urban Transport Use Cases with Solution for HPC Cloud

Retrieved on: 
Thursday, July 21, 2022

Fujitsu plans to provide its electromagnetic wave analysis solution to address this challenge.

Key Points: 
  • Fujitsu plans to provide its electromagnetic wave analysis solution to address this challenge.
  • To verify the effectiveness of its solution as a new cloud-service, Fujitsu conducted large-scale electromagnetic wave simulations in the following two areas.
  • The Japan Aerospace Exploration Agency (JAXA) utilized Fujitsu's wave analysis solution to conduct large-scale electromagnetic wave simulations evaluating the radio wave intensity in the X-ray spectrometer(4) of JAXA's X-ray imaging satellite XRISM(5).
  • Fujitsu conducted large-scale electromagnetic wave simulations utilizing its wave analysis solution to evaluate roadside-to-vehicle (high-speed 5G) communication quality between transmitters installed at intersections and receivers installed in vehicles.

Biocytogen and LiberoThera Achieve Milestone Progress in Co-Development of Fully Human GPCR Antibody Drugs

Retrieved on: 
Thursday, July 21, 2022

February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (LiberoThera) to co-develop fully human GPCR antibodies using Biocytogens advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoTheras outstanding membrane antigen preparation technology.

Key Points: 
  • February 1st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (LiberoThera) to co-develop fully human GPCR antibodies using Biocytogens advanced antibody discovery platform based on fully human antibody RenMabTM mice combined with LiberoTheras outstanding membrane antigen preparation technology.
  • These antibody clones exhibit high affinity binding to human CCR8 with species cross-reactivity and good manufacturability.
  • This undoubtedly validates that LiberoThera's advanced antigen preparation technology synergizes with our RenMice KO platform to generate diverse fully human antibodies.
  • Biocytogens streamlined fully human antibody development platform greatly accelerates the translation of GPCR research.

Bruker Announces Three New GHz NMR Systems Orders for Functional Structural Biology and Clinical Phenomics Research

Retrieved on: 
Monday, July 11, 2022

At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories.

Key Points: 
  • At the Euromar 2022 Conference, Bruker announced three new customer orders for GHz systems, which will incorporate novel, compact 1.0 GHz NMR magnets for structural biology applications and clinical research in single-story laboratories.
  • The new Ascend Evo 1.0 GHz NMR magnet, operating at 4.2 Kelvin, allows functional structural biology and clinical phenomics researchers to dive deeper into the structural details, binding and dynamics of molecular structures and complexes for fundamental cell biology and pathobiology research.
  • View the full release here: https://www.businesswire.com/news/home/20220711005260/en/
    Compact 1.0 GHz NMR magnet Ascend Evo for structural biology applications and clinical research in single-story laboratories (Graphic: Business Wire)
    A first new 1.0 GHz NMR order comes from the RIKEN Center for Biosystems Dynamics Research in Yokohama, Japan.
  • Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.

Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings

Retrieved on: 
Monday, May 30, 2022

TOKYO, May 30, 2022 - (JCN Newswire) - The supercomputer Fugaku, jointly developed by RIKEN and Fujitsu, has successfully retained the top spot for five consecutive terms in multiple major high-performance computer rankings including HPCG and Graph500 BFS (Breadth-First Search), and has also taken second place for the TOP500 and HPL-AI rankings.

Key Points: 
  • TOKYO, May 30, 2022 - (JCN Newswire) - The supercomputer Fugaku, jointly developed by RIKEN and Fujitsu, has successfully retained the top spot for five consecutive terms in multiple major high-performance computer rankings including HPCG and Graph500 BFS (Breadth-First Search), and has also taken second place for the TOP500 and HPL-AI rankings.
  • The results of the rankings were announced on May 30 at the ISC2022 High-Performance Computing Conference, which is currently being held in Hamburg, Germany.
  • The top ranking on Graph500 was won by a collaboration involving RIKEN, Kyushu University, Fixstars Corporation, and Fujitsu.
  • The results this time, first place in HPCG and Graph500, and second place in TOP500 and HPL-AI, show that Fugaku remains one of the world's leading supercomputers in the field of high-performance computing, where evolution and competition are fierce worldwide.

Fujitsu and RIKEN start joint research on next-generation IT drug discovery technology using the supercomputer Fugaku and simulation integrated AI

Retrieved on: 
Tuesday, May 17, 2022

The joint research project will leverage high performance computing technologies and the supercomputer Fugaku to accelerate simulation integrated AI that combines Fujitsu's DeepTwin AI technology, which accurately acquires quantitative features from complex data by unsupervised learning, with molecular dynamics simulation using RIKEN's AI drug discovery simulation technology.

Key Points: 
  • The joint research project will leverage high performance computing technologies and the supercomputer Fugaku to accelerate simulation integrated AI that combines Fujitsu's DeepTwin AI technology, which accurately acquires quantitative features from complex data by unsupervised learning, with molecular dynamics simulation using RIKEN's AI drug discovery simulation technology.
  • Based on this research, the two parties aim to develop a next-generation IT drug discovery technology with world-leading capabilities by the end of fiscal 2026.
  • RIKEN and Fujitsu will work together to transform the drug discovery process by truly integrating computing technologies such as the supercomputer Fugaku with leading edge AI and machine learning technologies.
  • In this joint research project, Fujitsu and RIKEN will collaborate to develop the world's best computational technology for drug discovery using the world-class supercomputer Fugaku.